Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
78,387
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$222B
12.94
$3.87
0.27
$1.23
1.64%
Price and volume
Market cap
$222B
Beta
0.27
52-week high
$111.79
52-week low
$45.05
Average daily volume
13M
Dividend rate
$1.23
Financial strength
Current ratio
0.784
Quick ratio
0.505
Long term debt to equity
51.947
Total debt to equity
59.065
Dividend payout ratio (TTM)
45.63%
Interest coverage (TTM)
17.27%
Profitability
EBITDA (TTM)
24,674.307
Gross margin (TTM)
84.26%
Net profit margin (TTM)
35.61%
Operating margin (TTM)
47.65%
Effective tax rate (TTM)
21.10%
Revenue per employee (TTM)
$616,620
Management effectiveness
Return on assets (TTM)
21.82%
Return on equity (TTM)
79.17%
Valuation
Price to earnings (TTM)
12.943
Price to revenue (TTM)
4.605
Price to book
8.53
Price to tangible book (TTM)
23.82
Price to free cash flow (TTM)
23.316
Free cash flow yield (TTM)
4.29%
Free cash flow per share (TTM)
2.146
Dividend yield (TTM)
2.46%
Forward dividend yield
1.64%
Growth
Revenue change (TTM)
20.90%
Earnings per share change (TTM)
24.26%
3-year revenue growth (CAGR)
25.65%
10-year revenue growth (CAGR)
12.15%
3-year earnings per share growth (CAGR)
31.20%
10-year earnings per share growth (CAGR)
15.33%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Bulls say / Bears say
Novo’s experimental next-generation obesity injection achieved up to 22% weight loss in early-stage trials, restoring investor optimism about its pipeline after previous setbacks. (Bloomberg)
The $2 billion agreement made in March with United Laboratories for a portfolio of multi-mechanism obesity drugs broadens Novo’s pipeline beyond semaglutide and could diversify its long-term growth prospects. (Bloomberg)
The FDA’s announcement in February that Ozempic and Wegovy supply issues were resolved highlights Novo Nordisk’s improved manufacturing capacity, lowering the risk of shortages and supporting stable market share. (Bloomberg)
In July, Novo Nordisk reduced its 2025 sales growth forecast to 8%–14% and cut its operating profit outlook to 10%–16% following weaker-than-expected U.S. sales of Wegovy and Ozempic, marking the second downward revision this year. (Reuters)
A recent Breakingviews analysis cautions that increasing competition from Roche, Pfizer, and more than 140 drugs in development could cut Novo's combined GLP-1 market share by half by 2030, putting its market dominance at risk. (Reuters Breakingviews)
Novo shares experienced a sharp drop in March after CagriSema trial results disappointed, casting doubt on the strength of its pipeline outside of semaglutide-based therapies. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss
WSJ13 hours ago
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
Reuters17 hours ago
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Investors Business Daily18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $222B as of October 31, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 12.94 as of October 31, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of October 31, 2025, the dividend rate is $1.23062 and the yield is 1.64%. Novo Nordisk has a payout ratio of 45.63% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.